A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. One out of seven will receive adalimumab (Humira®) and one out of seven will only receive inactive substances (placebo.)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Adalimumab; Tofacitinib

Criteria

Inclusion Criteria:

• Subjects must have active rheumatoid arthritis

• Subjects must have failed at least 1 disease modifying anti-rheumatic drug (DMARD)

• Subjects must not be currently taking any DMARD other than an antimalarial

Exclusion Criteria:

• Subjects who discontinued any previous TNF inhibitor therapy for either lack of benefit or safety.

• Subjects who previously received adalimumab (Humira®) therapy for any reason.

• Subjects with evidence of blood disorders, chronic infections or untreated tuberculosis